Trial Profile

A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABD 147 (Primary)
Indications Large cell carcinoma; Neuroendocrine carcinoma; Small cell lung cancer
Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept; Therapeutic Use
Sponsors Abdera Therapeutics

24 Apr 2026 Status changed from recruiting to active, no longer recruiting.
09 Sep 2025 According to Abdera Therapeutics media release, data from this study were presented in a poster session at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain.
09 Sep 2025 Results published in the Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com